Background: Vδ2 T cells are promising candidates for approaches of immunotherapy due to their unique pleiotropic functions; they were recently shown to enhance antiviral protection in hematopoietic stem cell transplantation (HSCT) recipients via innate effector activity and modulation of virus-specific adaptive T-cell response. Extracellular Vesicles (EVs) are key carriers of immunomodulatory signals and Vδ2-derived EVs (Vδ2-EVs) exhibit antitumor activity but their role in viral infection remain unclear. The aim of this study was to investigate the direct and immunomodulatory antiviral functions of Vδ2-EVs in healthy subjects and HSCT patients. Methods: The direct antiviral activity of Vδ2-EVs were tested in vitro using a model of Cytomegalovirus (CMV) replication. The immunomodulatory antiviral activities of Vδ2-EVs were evaluated in both healthy donors and HSCT recipients by functional immunological assays (cytokine release and proliferation capability of virus-specific T cells). Finally, their molecular cargo was characterized through miRNA sequencing. Results: Our findings reveal that Vδ2-EVs efficiently inhibit CMV replication, reducing the frequency of CMV-infected fibroblast cells. Moreover, Vδ2-EVs are taken up by myeloid cells and were able to activate antigen-presenting cells, leading to an increased frequency of CMV-specific T cells, as measured by IFN-γ production. Accordingly, Vδ2-EVs enhanced the proliferation of CMV-specific T-cell clones in HSCT pediatric recipients. Finally, the analysis of miRNA content in Vδ2-EVs highlighted the enrichment of miRNAs that target genes regulating critical antiviral response processes such as SOCS1. Conclusions: Altogether, this study provides new insights into the antiviral functions of Vδ2-EVs and underscores their translational therapeutic potential as modulators of antiviral immunity in immunocompromised settings. Supplementary information: The online version contains supplementary material available at 10.1186/s12967-026-08062-9.
Extracellular vesicles from activated Vδ2 T cells inhibit viral replication and enhance adaptive antiviral immunity / Bordoni, Veronica; Guarracino, Federica; Marocco, Francesco; Quattrocchi, Luca; Lorusso, Angela; Minutolo, Antonella; Garbo, Sabrina; Pellegrino, Marsha; Vinci, Mara; Matteucci, Claudia; Pagliara, Daria; Galaverna, Federica; Merli, Pietro; Battistelli, Cecilia; Locatelli, Franco; Agrati, Chiara. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - 24:1(2026), pp. 1-16. [10.1186/s12967-026-08062-9]
Extracellular vesicles from activated Vδ2 T cells inhibit viral replication and enhance adaptive antiviral immunity
Bordoni, Veronica;Marocco, FrancescoSecondo
Formal Analysis
;Garbo, Sabrina;Battistelli, Cecilia;
2026
Abstract
Background: Vδ2 T cells are promising candidates for approaches of immunotherapy due to their unique pleiotropic functions; they were recently shown to enhance antiviral protection in hematopoietic stem cell transplantation (HSCT) recipients via innate effector activity and modulation of virus-specific adaptive T-cell response. Extracellular Vesicles (EVs) are key carriers of immunomodulatory signals and Vδ2-derived EVs (Vδ2-EVs) exhibit antitumor activity but their role in viral infection remain unclear. The aim of this study was to investigate the direct and immunomodulatory antiviral functions of Vδ2-EVs in healthy subjects and HSCT patients. Methods: The direct antiviral activity of Vδ2-EVs were tested in vitro using a model of Cytomegalovirus (CMV) replication. The immunomodulatory antiviral activities of Vδ2-EVs were evaluated in both healthy donors and HSCT recipients by functional immunological assays (cytokine release and proliferation capability of virus-specific T cells). Finally, their molecular cargo was characterized through miRNA sequencing. Results: Our findings reveal that Vδ2-EVs efficiently inhibit CMV replication, reducing the frequency of CMV-infected fibroblast cells. Moreover, Vδ2-EVs are taken up by myeloid cells and were able to activate antigen-presenting cells, leading to an increased frequency of CMV-specific T cells, as measured by IFN-γ production. Accordingly, Vδ2-EVs enhanced the proliferation of CMV-specific T-cell clones in HSCT pediatric recipients. Finally, the analysis of miRNA content in Vδ2-EVs highlighted the enrichment of miRNAs that target genes regulating critical antiviral response processes such as SOCS1. Conclusions: Altogether, this study provides new insights into the antiviral functions of Vδ2-EVs and underscores their translational therapeutic potential as modulators of antiviral immunity in immunocompromised settings. Supplementary information: The online version contains supplementary material available at 10.1186/s12967-026-08062-9.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


